A systematic review of the economic evaluations of non-calcium-containing phosphate binders, sevelamer and Lanthanum, in end-stage renal disease patients with hyperphosphatemia

References

• Malberti F. Hyperphosphataemia: treatment options. Drugs. 2013 May;73(7):673–688.
   Google Scholar
• Moe SM, Glenn M. Chertow the case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697–703.
   PubMed Web of Science ®Google Scholar
• Eli A. Friedman calcium-based phosphate binders are appropriate in chronic renal failure. Clin J Am Soc Nephrol. 2006;1:704–709.
   PubMed Web of Science ®Google Scholar
• Eddington H, Heaf JG. Clinical management of disturbances of calcium and phosphate metabolism in dialysis patients. NDT Plus. 2009 Aug 1;2(4):267–272.
   PubMedGoogle Scholar
• Chan S, Au K, Francis RS, et al. Phosphate binders in patients with chronic kidney disease. Aust Prescr. 2017 Feb;40(1):10–14.
   PubMed Web of Science ®Google Scholar
• Marseille E, Larson B, Kazi DS, et al. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–124.
   PubMed Web of Science ®Google Scholar
• Rizk R. Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go BMC. Nephrology. 2016;17(75):1–4.
   Google Scholar
• Rizk R, Hiligsmann M, Karavetian M, et al. Economic evaluations of interventions to manage hyperphosphataemia in adult haemodialysis patients: a systematic review. Nephrology. 2016;21:178–187.
   PubMed Web of Science ®Google Scholar
• Komaba H, Moriwaki K, Kamae I, et al. Towards cost-effective strategies for treatment of chronic kidney disease-mineral and bone disorder in Japan. Ther Apher Dial. 2009;13(Suppl 1):28–35.
   Google Scholar
• Goto S, Komaba H, Fukagawa M, et al. Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder. Kidney Int Suppl. 2013;3:457–461.
   Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
   PubMed Web of Science ®Google Scholar
• Vegter S, Tolley K, Keith MS, et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a canadian payer perspective. Clin Ther. 2012;34:1531–1543.
   PubMed Web of Science ®Google Scholar
• Vegter S, Tolley K, Keith MS, et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health. 2011;14:852–858.
   PubMed Web of Science ®Google Scholar
• Brennan A, Akehurst R, Davis S, et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health. 2007;10:32–41.
   PubMed Web of Science ®Google Scholar
• Gros B, Galán A, González-Parra E, et al. Cost effectiveness of lanthanum carbonate in chronic kidney disease patients in Spain before and during dialysis. Health Econ Rev. 2015; 5(14)
   PubMedGoogle Scholar
• European Dialysis and Transplant Association Registry. Annual Report; 2006 [cited 2013 Oct 25]. Available from: http://www.era-edta-reg.org/files/annualreports/pdf/AnnRep2010.pdf
   Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–S20.
   PubMed Web of Science ®Google Scholar
• Goto S, Komaba H, Moriwaki K, et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol. 2011;6:1375–1384.
   PubMed Web of Science ®Google Scholar
• Hutchison AJ, Maes B, Vanwalleghem J, et al. lanthanum carbonate in hyperphosphatemia: a 6 month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract. 2005;100:8–19.
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Elgazzar HA, Chaplin S, et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin. 2008;24(2):601–608..
   PubMed Web of Science ®Google Scholar
• Bernard L, Mendelssohn D, Dunn E, et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ. 2013;16(1):1–9.
   PubMedGoogle Scholar
• Nguyen HV, Bose S, Finkelstein E. Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients BMC. Nephrol. 2016;17:45.
   Web of Science ®Google Scholar
• Suki W, Zabaneh R, Cangiano J, et al. The DCOR trial: a prospective, randomized trial assessing the impact on outcomes of sevelamer in dialysis patients. Philadelphia (PA): American Society of Nephrology; 2005.
   Google Scholar
• Manns B, Klarenbach S, Lee H, et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant. 2007;22:2867–2878.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Jaime Caro J, Wilson DA, et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health. 2005;8(5):549–561.
   PubMed Web of Science ®Google Scholar
• Huybrechts KF, Caro J, O’Brien JA. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. Value Health. 2009;12(1):16–19.
   Web of Science ®Google Scholar
• Cho J-H, Jang HM, Jung H-Y, et al. A real-world cost-effectiveness analysis of sevelamer versus calcium acetate in Korean dialysis patients. Clin Ther. 2018;40(1):123–134.
   Web of Science ®Google Scholar
• Ruggeri M, Bellasi A, Cipriani F, et al. Sevelamer is cost effective versus calcium carbonate for the first-line treatment of hyperphosphatemia in new patients to hemodialysis: a patient-level economic evaluation of the INDEPENDENT-HD study. J Nephrol. 2015;28:593–602..
   PubMed Web of Science ®Google Scholar
• Habbous S, Przech S, Martin J, et al. Cost-effectiveness of first-line sevelamer and lanthanum versus calcium based binders for hyperphosphatemia o chronic kidney disease. Value Health. 2018;21:318–325.
   PubMed Web of Science ®Google Scholar
• Park H, Rascati KL, Keith MS, et al. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health. 2011;14:1002–1009.
   PubMed Web of Science ®Google Scholar
• Grima DT, Bernard MLM, Dunn ES, et al. Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis. PharmacoEconomics. 2012;30:981–989.
   PubMed Web of Science ®Google Scholar
• Koiwa R, Yokoyama K, Fukagawa M, et al. Efficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: a randomized, open-label, multicentre, 12-week phase III study. Nephrology. 2017;22:293–300.
   PubMed Web of Science ®Google Scholar